Browse the corpus

Evinacumab is a monoclonal antibody approved for adjunctive therapy for patients aged 5 years and older with homozygous familial hypercholesterolemia whose low-density lipoprotein (LDL) cholesterol remains elevated despite traditional interventions. Evinacumab is an angiopoietin-like protein 3 (ANGPTL3) inhibitor administered via intravenous infusion. This activity reviews the indications, mechanism of action, adverse reactions, contraindications, and toxicities of evinacumab and highlights the role of the interprofessional team in caring for patients with homozygous familial hypercholesterolemia and related conditions. Objectives: Identify patients who may benefit from evinacumab therapy based on their clinical history. Differentiate homozygous familial hypercholesterolemia from other common lipid disorders. Evaluate and manage common adverse drug reactions associated with evinacumab therapy. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from evinacumab therapy. Access free multiple choice questions on this topic.

There is no significant toxicity associated with evinacumab therapy apart from embryofetal toxicity.[15] There is no antidote to evinacumab. There are no known contraindications in patients with either renal or hepatic impairment. Further studies should be performed to more accurately assess any long-term complications or adverse effects that may arise from evinacumab therapy.[16][17] If patients experience adverse reactions to the evinacumab, they should consult their prescribing or primary care practitioner as quickly as possible.

HoFH is a hereditary condition that negatively affects lipid metabolism. HoFH leads to high cholesterol levels, in particular, high LDL-C levels. High cholesterol levels predispose to early cardiovascular disease, which may lead to increased atherosclerosis. Increased atherosclerosis can lead to the development of either stroke or myocardial infarction. Evinacumab is a novel monoclonal antibody medication used to treat HoFH. This medication may effectively treat patients with refractory outcomes to more conventional pharmacologic and lifestyle modifications. Evinacumab has been shown to lower LDL-C levels effectively in patients with HoFH. Evinacumab may be best used with other lipid-lowering medications and dietary and lifestyle modifications to achieve optimum results.[18] Evinacumab does require prior authorization before administration, with specific guidelines needing to be met, which may vary per insurance company. Another critical factor to consider before the administration of evinacumab is the cost.[19] Due to the novelty of the medication, the expense of evinacumab may be quite high, with the annual wholesale cost as high as $450,000. Citing the substantial price of $450,000 per person per year for evinacumab, the National Lipid Association emphasizes the urgency for cost-effective approaches by proposing a novel technique: customizing doses using weight bands, a departure from the conventional mg/kg method and dose individualization as per the LDL-C response. This method can accomplish a 34% reduction in cost without compromising efficacy and offers a promising strategy to reduce the financial burden.[20] Managing HoFH usually requires the expertise of cardiologists and endocrinologists. However, primary care practitioners are essential to the optimal care of patients with HoFH patients as they routinely check laboratory values, including lipid panels. Pharmacists also play an indispensable role in managing HoFH; multiple lipid-lowering therapies must be rigorously trialed before initiating evinacumab therapy. Other healthcare team members integral to evinacumab therapy are nurses, many of whom will start the intravenous lines and initiate the transfusion therapy. Many will be responsible for preparing the infusion and ensuring proper dosage and administration.

Managing HoFH usually requires the expertise of cardiologists and endocrinologists. However, primary care practitioners are essential to the optimal care of patients with HoFH patients as they routinely check laboratory values, including lipid panels. Pharmacists also play an indispensable role in managing HoFH; multiple lipid-lowering therapies must be rigorously trialed before initiating evinacumab therapy. Other healthcare team members integral to evinacumab therapy are nurses, many of whom will start the intravenous lines and initiate the transfusion therapy. Many will be responsible for preparing the infusion and ensuring proper dosage and administration. Patients should feel comfortable with their treatment plan and receive informed consent of all the risks and benefits before initiating treatment. In the event of anaphylaxis, emergency department practitioners should rapidly stabilize the patient. An interprofessional team approach with open communication between primary care practitioners, specialists, nurses, and pharmacists can optimize the patient outcomes of evinacumab therapy.